---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-24-000006"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:18:20.492942+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M

## Summary
- Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).
- Adjusted gross margin expanded to 56% (from 41% Q4 2022); exome/genome margin >60%.
- Adjusted net loss narrowed to $17.8M, a 76% improvement YoY; cash burn reduced 51% YoY.
- FY2024 revenue guidance $220-230M; reiterates path to profitability in 2025.
- Exome/genome test volume 15,663 in Q4 (+99% YoY); 49,439 full year.

## SEC filing metadata
- accession: 0001818331-24-000006
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/0001818331-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/wgs-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-24-000006
- JSON: https://secwatch.observer/filing/0001818331-24-000006.json
- Plain text: https://secwatch.observer/filing/0001818331-24-000006.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported the fourth quarter and full year of 2023 results: revenue $58.1 million, net income $17.8 million. Guidance initiated.
  - Period: the fourth quarter and full year of 2023
  - Revenue: $58.1 million
  - Net income: $17.8 million
  - Guidance: initiated
  - Result: reported results
  source text: reach profitability in 2025.” Fourth Quarter and Full Year 2023 Financial Results (Unaudited) 1,2,3 Revenues Fourth quarter 2023: • Revenues from continuing operations grew to $58.1 million, an increase of 27% year-over-year and 15% sequentially. ◦ Total company revenues were $57.4 million. • Exome and genome test revenue grew to $39.2 million, an increase of 68%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/0001818331-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.